Skip to main content
Erschienen in: Annals of Hematology 2/2004

01.02.2004 | Case Report

Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab

verfasst von: E. M. Buda-Okreglak, J. J. Drabick, N. R. Delaney

Erschienen in: Annals of Hematology | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Acute adverse reactions to rituximab treatment have been previously described in association with initiation of therapy. We describe a novel delayed proinflammatory syndrome which occurred at, or near, the completion of a 4-week dose-intense course with rituximab in a 58-year-old man with Waldenstrom's macroglobulinemia, and which mimicked acute rheumatoid arthritis affecting the hands and the knees. This syndrome was associated with an increase in acute phase reactants, and the clinical symptoms were temporally reproducible, although decreased in severity, with subsequent rituximab therapy, and each time responded to prednisone. This is the first report on an acute rheumatoid-like flare occurring in association with rituximab therapy. This phenomenon is all the more intriguing in that rituximab has been used to treat refractory rheumatoid arthritis. Potential etiologic mechanisms and management of this newly described phenomenon are discussed.
Literatur
1.
Zurück zum Zitat Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791–795PubMed Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791–795PubMed
2.
Zurück zum Zitat Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754–758CrossRefPubMed Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754–758CrossRefPubMed
3.
Zurück zum Zitat Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143PubMed Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143PubMed
4.
Zurück zum Zitat Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69CrossRef Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69CrossRef
5.
Zurück zum Zitat De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029–2033CrossRefPubMed De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029–2033CrossRefPubMed
6.
Zurück zum Zitat Edwards JC, Leandro MJ, Cambridge G (2002) B-lymphocyte depletion in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 30:824–828PubMed Edwards JC, Leandro MJ, Cambridge G (2002) B-lymphocyte depletion in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 30:824–828PubMed
7.
Zurück zum Zitat Jensen M, Winkler U, Manzke O, Diehl V, Engert A (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 77:89–91CrossRefPubMed Jensen M, Winkler U, Manzke O, Diehl V, Engert A (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 77:89–91CrossRefPubMed
8.
Zurück zum Zitat Jeyarajah DR, Thistlethwaite HR Jr (1993) General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 25 [Suppl 1]:16–20 Jeyarajah DR, Thistlethwaite HR Jr (1993) General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 25 [Suppl 1]:16–20
9.
Zurück zum Zitat Kelaidi C, Tulliez M, Lecoq-Lafon C, Pham X-V, Kahan A, Dreyfus S, Bouscany D (2002) Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia 16:2173–2174CrossRefPubMed Kelaidi C, Tulliez M, Lecoq-Lafon C, Pham X-V, Kahan A, Dreyfus S, Bouscany D (2002) Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia 16:2173–2174CrossRefPubMed
10.
Zurück zum Zitat Leandro MJ, Edwards JCW, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888CrossRefPubMed Leandro MJ, Edwards JCW, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888CrossRefPubMed
11.
Zurück zum Zitat Lim LC, Koh LP, Tan P (1999) Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 17:1962–1963 Lim LC, Koh LP, Tan P (1999) Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 17:1962–1963
12.
Zurück zum Zitat Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W (2001) Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 60:892–893PubMed Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W (2001) Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 60:892–893PubMed
13.
Zurück zum Zitat Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710–4718PubMed Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710–4718PubMed
14.
Zurück zum Zitat Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanoulides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC (2001) The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. J Immunother 24:272–279CrossRef Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanoulides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC (2001) The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. J Immunother 24:272–279CrossRef
15.
Zurück zum Zitat Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217–2224PubMed Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217–2224PubMed
Metadaten
Titel
Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab
verfasst von
E. M. Buda-Okreglak
J. J. Drabick
N. R. Delaney
Publikationsdatum
01.02.2004
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 2/2004
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0747-5

Weitere Artikel der Ausgabe 2/2004

Annals of Hematology 2/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.